Director Share Distribution
Three directors received ordinary shares totalling 46,268 from terminated employee benefit trust distribution.
- Shares received by Ajan Reginald 34,432
- Shares received by Dr Darrin Disley 9,146
- Shares received by Sir Martin Evans 2,690
- Ajan Reginald holding after distribution 12,346,413 (9.1%)
- Dr Darrin Disley holding after distribution 2,024,196 (1.5%)
- Sir Martin Evans holding after distribution 2,690 (0.0%)
Select text to share a quote on X · sign in to keep highlights & notes in your COIL notes
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immunology and oncology markets, has been advised by VG Corporate Trustee Limited that an employee benefit trust (unrelated to the Company), has been terminated and the trust assets have been distributed to the beneficiaries. As a result of the trust distribution, three Directors of the Company (Ajan Reginald, Dr Darrin Disley and Sir Marin Evans) have received ordinary shares of £0.01 each in the Company ("Ordinary Shares"), as detailed below:
| Director | Number of Ordinary Shares Received for Nil Consideration | Number of Ordinary Shares Now Held | % of Company's Issued Capital |
| Ajan Reginald | 34,432 | 12,346,413 | 9.1% |
| Dr Darrin Disley | 9,146 | 2,024,196 | 1.5% |
| Sir Martin Evans | 2,690 | 2,690 | 0.0% |
| a) | Name | Ajan Reginald | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Executive Officer | |
| b) | Initial notification /Amendment | Initial | |
| a) | Name | Roquefort Therapeutics plc | |
| b) | LEI | 254900P4SISIWOR9RH34 | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.01 par value ISIN: GB00BMDQ2T15 | |
| b) | Nature of the transaction | Trust distribution of 34,432 ordinary shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| 0 pence per share | 34,432 | ||
| d | Aggregated information - Aggregated volume - Price | - 34,432 - 0p | |
| e) | Date of the transactions | 3 December 2024 | |
| f) | Place of the transactions | London Stock Exchange (XLON); Main Market | |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Dr Darrin Disley | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification /Amendment | Initial | |
| a) | Name | Roquefort Therapeutics plc | |
| b) | LEI | 254900P4SISIWOR9RH34 | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.01 par value ISIN: GB00BMDQ2T15 | |
| b) | Nature of the transaction | Trust distribution of 9,146 ordinary shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| 0 pence per share | 9,146 | ||
| d | Aggregated information - Aggregated volume - Price | - 9,146 - 0p | |
| e) | Date of the transactions | 3 December 2024 | |
| f) | Place of the transactions | London Stock Exchange (XLON); Main Market | |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Sir Martin Evans | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification /Amendment | Initial | |
| a) | Name | Roquefort Therapeutics plc | |
| b) | LEI | 254900P4SISIWOR9RH34 | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.01 par value ISIN: GB00BMDQ2T15 | |
| b) | Nature of the transaction | Trust distribution of 2,690 ordinary shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| 0 pence per share | 2,690 | ||
| d | Aggregated information - Aggregated volume - Price | - 2,690 - 0p | |
| e) | Date of the transactions | 3 December 2024 | |
| f) | Place of the transactions | London Stock Exchange (XLON); Main Market |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.